Human immunodeficiency virus type 1 latency model for high-throughput screening.
Antimicrobial agents and chemotherapy 2005 Dec 1; 49(12):5185-8
Micheva-Viteva S S, Pacchia A AL, Ron Y Y, Peltz S SW, Dougherty J JP
Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, USA.
Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.

